Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK plc commences share buyback programme
GSK plc announces the commencement of its share buyback programme, as announced in its 2024 full year results announcement.
Download (PDF, 114.3KB) -
GSK completes acquisition of IDRx, Inc.
GSK plc has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, clinical-stage biopharmaceutical company.
Download (PDF, 143.1KB) -
GSK announces Dr Gavin Screaton to join the Board as Non-Executive Director
GSK plc has today announced that Dr Gavin Screaton has been appointed to the Board of the Company as a Non-Executive Director.
Download (PDF, 129.2KB) -
Nucala (mepolizumab) application for COPD accepted for review in China
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Download (PDF, 179.3KB) -
Penmenvy, GSK’s 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y).
Download (PDF, 187.8KB) -
GSK delivers strong 2024 performance with further improvement to long-term growth outlook
Q4 and full year 2024 performance highlights
Download (PDF, 853.9KB) -
European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria + Rekambys for HIV treatment in adolescents
Vocabria + Rekambys (cabotegravir + rilpivirine) is the first and only complete long-acting injectable for the treatment of HIV.
Download (PDF, 146.2KB) -
Depemokimab accepted for review by the European Medicines Agency for use in asthma with type 2 inflammation and CRSwNP
If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing.
Download (PDF, 155.4KB) -
Depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP
If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing
Download (PDF, 194.1KB) -
GSK and Oxford establish the GSK-Oxford Cancer Immuno-Prevention Programme to advance novel cancer research
Collaboration unites GSK and Oxford’s complementary expertise in the science of the immune system, vaccines and cancer biology.
Download (PDF, 173.0KB) -
GSK’s Shingrix new prefilled syringe presentation accepted for review by European Medicines Agency
Over 25 million people in Europe have received GSK’s shingles vaccine since 2018.
Download (PDF, 154.9KB) -
European Commission expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer
Expanded approval includes MMRp/MSS tumours, which represent approximately 75% of endometrial cancer cases.
Download (PDF, 174.7KB) -
GSK enters agreement to acquire IDRx, Inc.
Acquisition adds to GSK’s growing portfolio in gastrointestinal (GI) cancers
Download (PDF, 159.1KB) -
GSK’s Shingrix new prefilled syringe presentation accepted for review by US FDA
If approved, the new presentation will offer a convenient administration option to healthcare professionals.
Download (PDF, 219.7KB) -
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma
Regulatory designation based on promising early data in this rare bone cancer.
Download (PDF, 144.6KB) -
GSK’s Nucala (mepolizumab) approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps
This is the third indication for mepolizumab in China for an IL-5 mediated condition
Download (PDF, 193.2KB) -
GSK announces FIRST trial met its primary endpoint of progression free survival in first line advanced ovarian cancer
GSK announces headline results from the FIRST-ENGOT-OV44 phase III trial.
Download (PDF, 213.0KB) -
ViiV Healthcare announces CHMP positive opinion for Vocabria + Rekambys, the first and only complete long-acting HIV treatment, for adolescents in Europe
Vocabria + Rekambys is the first and only complete long-acting regimen for the treatment of HIV, reducing dosing days from 365 to 6 per year
Download (PDF, 104.2KB) -
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives EMA Priority Medicines (PRIME) Designation in relapsed extensive-stage small-cell lung cancer
Regulatory designation based on promising preliminary clinical data.
Download (PDF, 146.9KB) -
Jemperli (dostarlimab) receives US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer
Designation based on data showing no evidence of disease in 100% of all 42 patients who completed treatment with dostarlimab.
Download (PDF, 183.9KB)
